Company / Total Debt
Apellis Pharmaceuticals, Inc. Total Debt History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$93.0M
FY2023
5-year range
$92.7M / $93.0M
FY2019-FY2023
Trend
+0.3%
vs FY2022
Sector context
#63 of 83
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s total debt of $93M is lower than 76% of companies in the Health Care sector (FY2023). Increased from $27M to $93M over the past 6 years.
Based on SEC 10-K filings.
$93M in FY2023.
Increased from $27M to $93M over the past 6 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 83This company $93.0M Sector average $6.2B
▼
-98.5% below sector average
Key checks
Key Insights
- In FY2023, total debt increased 0.3% year-over-year.
- Ranks #63 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $93.0M | +0.3% |
| FY2022 | $92.7M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $27.0M | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026